Immunic Inc. (IMUX) had the kind of Friday that gets investors' attention. Shares surged more than 23% on volume of 55.97 million shares, compared to a typical daily average of just 1.62 million. That's not a typo—we're talking about 34 times normal trading activity.

The catalyst? An oversubscribed private placement that brings in up to $400 million, paired with a management reshuffle that signals the company is gearing up for its next phase of growth.

Show Me the Money

Here's how the financing breaks down. Immunic is issuing 229.08 million pre-funded warrants priced at $0.873 each, delivering $200 million in immediate gross proceeds. These aren't your typical warrants—pre-funded means investors pay almost the entire exercise price upfront, with just a nominal amount left to exercise later.

But wait, there's more. The company is also issuing regular warrants to purchase up to 229.076 million additional shares at $0.873 per share. If those get exercised, that's another $200 million coming through the door. So the total potential haul is $400 million, assuming full participation.

That cash isn't sitting idle. Immunic plans to use the funds to complete its Phase 3 ENSURE trial in relapsing multiple sclerosis, with topline data expected by the end of 2026. The timeline from there is fairly clear: submit a New Drug Application to U.S. regulators in mid-2027, targeting potential approval in 2028.

The company is also working toward launching a Phase 3 program in primary progressive multiple sclerosis later this year, which they estimate will take roughly 3.5 to 4 years to complete.

New Faces in the Executive Suite

Alongside the financing news, Immunic announced meaningful leadership changes. Simona Skerjanec has been elevated to interim Chairperson of the Board, and the company has kicked off a search for a new CEO with commercial experience—a logical move as they shift from clinical-stage biotech to potential product launches.

Co-Founder and current CEO Daniel Vitt isn't leaving entirely. He's transitioning to a new senior executive position focused on strengthening the company's scientific strategy. It's the kind of move you see when a company realizes the skills needed to discover drugs aren't always the same skills needed to sell them.

What the Charts Say

Technically speaking, Immunic is showing serious momentum. The stock is trading 63.2% above its 20-day simple moving average and 50.5% above its 100-day SMA. Over the past year, shares have climbed 14.46% and are sitting closer to their 52-week highs than lows.

The RSI stands at 69.12, which is neutral territory, while the MACD is above its signal line—a bullish signal. The combination suggests mixed momentum with room for continued upside. Traders are watching key resistance at $1.50 and support at $1.00.

Sector Context

Immunic's 24.12% daily gain is crushing the broader healthcare sector, which rose just 1.54% on Friday. Over the past 30 days, the sector has gained a modest 0.32%, while the 90-day picture looks better at 4.40%. Healthcare is currently ranked second among all sectors, providing a favorable backdrop for the company's commercial transition.

Analysts seem to like the story. The stock carries a Buy rating, with recent actions including D. Boral Capital maintaining a Buy rating while lowering its target to $4, and HC Wainwright maintaining a Buy with an $8 target.

At the time of publication Friday, Immunic shares traded at $1.07, up 23.56%.